Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 9/20 | 0.38 |
| ▸ | JAK2 | O60674 | 8/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27378764 | 0.90 | TNKS2 (0.39) | TNKS2ALDH1A1KMT2AMEN1RAB9A | |
| SCHEMBL29326549 | 0.85 | HSD17B10 (0.38) | ALDH1A1KMT2AMEN1RAB9AHSD17B10 | |
| SCHEMBL29326563 | 0.80 | TNKS2 (0.56) | TNKS2BTKJAK2TP53PAK1 | |
| SCHEMBL29326565 | 0.79 | TNKS2 (0.50) | TNKS2ALDH1A1KMT2AMEN1HSD17B10 | |
| SCHEMBL29326500 | 0.76 | TNKS2 (0.60) | TNKS2TP53PAK1KDM4EHTT | |
| SCHEMBL27378784 | 0.75 | ALDH1A1 (0.34) | ALDH1A1KMT2AMEN1RAB9AHSD17B10 | |
| SCHEMBL29326524 | 0.73 | TNKS2 (0.44) | TNKS2TP53PAK1KDM4EHTT | |
| SCHEMBL29326509 | 0.73 | TNKS2 (0.53) | TNKS2ALDH1A1TP53PAK1KDM4E | |
| SCHEMBL29326363 | 0.73 | TNKS2 (0.50) | TNKS2TDP1TP53KDM4EHTT | |
| SCHEMBL30702006 | 0.72 | TNKS2 (0.53) | TNKS2TP53PAK1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | TNKS2 619/4885ALDH1A1 3259/4885KMT2A 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.